Unknown

Dataset Information

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.


ABSTRACT:

Background

The clinical meaningfulness of the effects of recently approved disease-modifying treatments (DMT) in Alzheimer's disease is under debate. Available evidence is limited to short-term effects on clinical rating scales which may be difficult to interpret and have limited intrinsic meaning to patients. The main value of DMTs accrues over the long term as they are expected to cause a delay or slowing of disease progression. While awaiting such evidence, the translation of short-term effects to time delays or slowing of progression could offer a powerful and readily interpretable representation of clinical outcomes.

Methods

We simulated disease progression trajectories representing two arms, active and placebo, of a hypothetical clinical trial of a DMT. The placebo arm

SUBMITTER: Jonsson L 

PROVIDER: S-EPMC10903002 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature